Qingxia Li

1 clinical trials · Sponsor

Record	Firm	Date
The Efficacy and Safety of Iparomlimab/Tuvonralimab (Anti PD-1/CTLA-4) Combined With Albumin-bound Paclitaxel in Second-line Treatment of Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (NCT07139587)	Qingxia Li	2025-09-01

Every clearance here is in the API, with alerts when new ones post.